reported that TYRO3 can promote the development of the tumor microenvironment by reducing the ratio of M1/M2 macrophages while inhibiting TYRO3 can promote tumor ferroptosis and make drug-resistant tumors sensitive to PD-1 therapy (24). This evidence concerns the gene TYRO3 and neoplasm.